Kisqali combined with an aromatase inhibitor improved iDFS in hormone receptor-positive, HER2-negative early breast cancer, with a 30% risk reduction in DDFS and distant recurrence-free survival. The ...
The FDA approval was based on NATALEE, a randomized (1:1), open-label, multicenter, multinational trial in adults of any sex or menopausal status with hormone receptor–positive, HER2-negative stage II ...
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase ...
A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled "PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast ...
Postmenopausal women with hormone-receptor–positive breast cancer who had received 5 years of adjuvant endocrine therapy were randomly assigned to an additional 2 years or 5 years of therapy with the ...
Recently, mortality from breast cancer has decreased due to effective endocrine therapies;. However, many recovered patients have reported the development of type 2 diabetes mellitus (T2DM) following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results